Table 3.
Synthetic and natural products that mediate their anticancer effects.
| Compounds | Targeting pathways | Cancer types | References |
|---|---|---|---|
| Metformin | MiR-497/proline-, glutamic acid-, and leucine-rich protein-1(PELP1) axis/GSDMD | Esophageal cancer | [128] |
| PLK1 inhibitors | Bax/Caspase-3/GSDME | Esophagus cancer | [60] |
| LDC7559 | GSDMD | Esophagus cancer | [146] |
| Chemotherapeutic medicines such actinomycin-D, doxorubicin (DOXO), topotecan, and bleomycin | Caspase-1, Caspase-3, GSDMD/GSDME/DFNA/eEF-2K | Lung cancer | [18] |
| Paclitaxel and cisplatin | Caspase-3/GSDME | Lung cancer | [130] |
| Chalcone derivative-8 | GSDME/ROS | Lung cancer | [131] |
| N-substituted EF24 analog 13d | NF-kB/caspase-3 | Lung cancer | [132] |
| L61H10 | NF-kB | Lung cancer | [133] |
| 4-hydroxybenzoic acid (4-HBA) | Caspase-1/IL-1β/and IL-18 | Lung cancer | [147] |
| Lobaplatin | ROS/JNK/Caspase-3/GSDME | Colon cancer | [122] |
| 5-fluorouracil | caspase-3/GSDME | Gastric cancer | [62] |
| Piperlongumine-analogue (PL-a) L50377 | NF-kB/ROS | NSCLC cell | [134] |
| Alpha-NETA | GSDMD/Caspase-4 | Ovarian cancer | [110] |
| Decitabine (DAC) | Caspase-3/GSDME | Malignant cells | [135] |
| Anthocyanidins (ANTH) | NLRP3/caspase-1/IL-1β/GSDMD | Oral squamous cell carcinoma (OSCC) | [137] |
| Galanin | GSDME | Glioblastoma | [138] |
| Omega-3 fatty acids | Caspase-1/IL-1β/GSDMD | Breast cancer | [114] |
| Dipeptidyl peptidases (DPPs) | Caspase-1 | Acute myeloid leukemia (AML) | [142] |
| Necrosulfonamide | GSDMD | Myeloid leukemia | [145] |